Arrowstreet Capital, Limited Partnership Vertex Pharmaceuticals Inc Transaction History

Arrowstreet Capital, Limited Partnership

$114 Billion
Q2 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $40,292 - $45,328	141 Added 2.77%	5,233 $1.51 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $1.29 Million - $1.44 Million	-4,698 Reduced 47.99%	5,092 $1.47 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $2.3 Million - $2.86 Million	9,790 New	9,790 $2.76 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $5.37 Million - $6.33 Million	-24,249 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $4.29 Million - $5.42 Million	24,249 New	24,249 $5.33 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $58.8 Million - $65.8 Million	-324,105 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $20 Million - $23.6 Million	106,544 Added 48.97%	324,105 $65.3 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $35.9 Million - $41.8 Million	-173,238 Reduced 44.33%	217,561 $46.8 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $61 Million - $81.4 Million	294,786 Added 307.03%	390,799 $92.4 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $3.43 Million - $4.07 Million	13,431 Added 16.26%	96,013 $26.1 Million
Q2 2020 Aug 12, 2020	BUY	$225.48 - $295.8 $2.8 Million - $3.67 Million	12,406 Added 17.68%	82,582 $24 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $14 Million - $17.4 Million	70,176 New	70,176 $16.7 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $572,815 - $769,354	-3,436 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $117 Million - $132 Million	-704,946 Reduced 99.51%	3,436 $582,000
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $21.9 Million - $25.3 Million	-133,127 Reduced 15.82%	708,382 $130 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $8.08 Million - $9.61 Million	49,336 Added 6.23%	841,509 $155 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $1.47 Million - $1.86 Million	-9,694 Reduced 1.21%	792,173 $131 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $180 Million - $207 Million	-1,073,366 Reduced 57.24%	801,867 $155 Million
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $36.4 Million - $42.5 Million	-249,983 Reduced 11.76%	1,875,233 $319 Million
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $140 Million - $163 Million	921,995 Added 76.63%	2,125,216 $346 Million
Q4 2017 Feb 09, 2018	BUY	$137.28 - $155.55 $78.3 Million - $88.7 Million	570,287 Added 90.1%	1,203,221 $180 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $93.8 Million - $103 Million	632,934	632,934 $96.2 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

Capital World Investors Los Angeles, CA

26.7M
Shares

$13.4 Billion
2.1% of portfolio
Vanguard Group Inc Valley Forge, PA

23M
Shares

$11.5 Billion
0.21% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$10.7 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.7M
Shares

$5.89 Billion
0.24% of portfolio
Capital Research Global Investors Los Angeles, CA

8.54M
Shares

$4.29 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account